Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors

Molecular Genetics and Metabolism

Volumn 76, Issue 3, 2002, Pages 225-233

  Bramlett, Kelli S ^a   Burris, Thomas P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

LXXLL; Nuclear receptor; p160; SERM; SRC 1; Steroid receptor

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; CELL NUCLEUS RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; FLUORESCENCE; PRIORITY JOURNAL; TECHNOLOGY;

AMINO ACID SEQUENCE; ESTRADIOL; FLUORESCENCE; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES;

EID: 0036376622     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(02)00043-4     Document Type: Article

References (38)

1. The nuclear receptor superfamily
2. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
3. The nuclear receptor superfamily: The second decade
4. The RXR heterodimers and orphan receptors
5. Coactivators and corepressors
6. Nuclear receptor coactivators: Cellular and molecular biology
7. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors
8. Molecular basis of agonism and antagonism in the oestrogen receptor
9. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
10. Structural insights into the mode of action of a pure aniestrogen
11. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full agonist
12. Development of peptide antagonists that target estrogen receptor β-coactivator interactions
13. Ligands specify coactivator NR box affinity for estrogen receptor subtypes
14. Sequence and characterization of a coactivator for the steroid receptor superfamily
15. GRIP1, a transcriptional coactivator for the AF2 transactivation domain of steroid thyroid, retinoid and vitamin D receptors
16. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function of AF-2 of nuclear receptors
17. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
18. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
19. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF-2
20. TRAM-1, a novel 160 kDa thyroid hormone receptor activator molecule exhibits distinct properties from steroid receptor coactivator-1
21. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
22. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity
23. A signature motif in transcriptional coactivators mediates binding to nuclear receptors
24. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor
25. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors α and β
26. Selection of estrogen receptor β- and thyroid hormone receptor β-specific coactivator-mimetic peptides using recombinant peptide libraries
27. Core LXXLL motif sequences in CREB-binding protein, SRC-1 and RIP140 define affinity and selectivity for steroid and retinoid receptors
28. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
29. Estrogen receptor modulators: Effects in non-traditional target tissues
30. Effects of tamoxifen on bone mineral density in postmenopausal women
31. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial
32. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
33. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in overiectomized rats
34. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres
35. Circumventing tamoxifen resistance in breast cancer using antiestrogens that induce unique conformational changes in the estrogen receptor
36. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription
37. Peptide antagonists of the human estrogen receptor
38. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ